Home » Newsletters » BioWorld Science

BioWorld Science

April 25, 2000

View Archived Issues

ID Biomedical licenses oral E. coli vaccine technology

Long-term outcomes show good safety profile for Celebrex

Company Profile: IDM

C5 proven necessary for active arthritis; data support development of 5G1.1

Delsys develops novel solid oral dosage forms

Basulin completes proof-of-principle study

ML-3000 enters phase III trial in osteoarthritis

Ajinomoto prepares benzene derivatives useful for inflammation, etc.

Zonagen submits final results of two-year rat study of Vasomax to FDA

Millennium reports Q1 2000 progress

Prostanoid receptor ligands reported in recent patent literature by Ono

Kyorin patents new cell adhesion inhibitors

Potential new treatment for traumatic brain injury under study at Boehringer Ingelheim

Discovery of novel cytokine disclosed by Schering-Plough

Novel interferon with application in therapy discovered by ZymoGenetics

Zeria updates status of GI pipeline

Progen's angiogenesis inhibitor slows tumor growth in rats

Watanidipine advances toward launch in major Asian countries

Human data indicate potential of cefoselis in oral and maxillofacial infections

New Alzheimer's disease therapy cleared by FDA

Lipophilic platinum complex superior to cisplatin in rat hepatic tumor model

FDA approves Camptosar as first-line treatment of metastatic colorectal cancer

SafeScience's phase II trial of GBC-590 expanded

Novelos Therapeutics initiates first U.S. trial of BAM-002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.